SystImmune, Bristol Myers Squibb, Biokin, Izalontamab Brengitecan, Iza-Bren, BL-B01D1, PANKU-Lung01, Phase 3 Clinical Trial, EGFR-Mutated NSCLC, Non-Small Cell Lung Cancer,

BOTHELL, Wash., AND PRINCETON, N.J. — October 26, 2026 SystImmune, Inc. and Bristol Myers Squibb (NYSE: BMY) announced positive...